Large Study Finds Prenatal Tylenol Does Not Raise Autism or ADHD Risk
A Hong Kong sibling-matched cohort study finds acetaminophen during pregnancy unlikely to cause autism or ADHD in children.
Summary
A large population-based study from Hong Kong found that taking acetaminophen (Tylenol) during pregnancy does not increase a child's risk of autism spectrum disorder or ADHD. Using sibling-matched analyses — which control for shared family genetics and environment — researchers found no meaningful association. Earlier studies that showed a link likely reflected underlying health differences in women who needed pain relief, not the drug itself. Negative-control analyses using pre-pregnancy acetaminophen use confirmed this confounding effect. The findings align with prior sibling studies from Japan, Norway, Sweden, and Taiwan, and add important reassurance for pregnant women who require pain or fever management.
Detailed Summary
For years, observational studies suggested a possible link between acetaminophen use during pregnancy and neurodevelopmental conditions like autism and ADHD in children, prompting public concern and even government warnings. A rigorous new study published in JAMA Internal Medicine now offers strong evidence that this association was likely a statistical artifact, not a causal relationship.
Researchers at the University of Hong Kong analyzed a large population-based cohort using sibling-matched data — a design that controls for shared genetic background and family environment. In these matched analyses, prenatal acetaminophen exposure showed no increased risk for autism (adjusted HR 1.00) or ADHD (adjusted HR 1.01). Crucially, results held regardless of timing, dosage, or frequency of use during pregnancy.
The key methodological insight came from negative-control analyses. When researchers examined acetaminophen use in the year before conception — a period when the drug could not possibly affect fetal brain development — they found similar elevated hazard ratios as during pregnancy. This tells researchers that women who take acetaminophen are systematically different from those who do not, likely due to underlying health conditions like fever, infection, or chronic pain, which may themselves contribute to neurodevelopmental risk.
Conventional cohort analyses, which showed HRs of 1.17 for autism and 1.23 for ADHD, failed to account for this confounding. The sibling-comparison design effectively removes it. These findings align with four prior sibling studies conducted in Japan, Norway, Sweden, and Taiwan, all of which found no increased neurodevelopmental risk.
For pregnant women and their clinicians, this study provides meaningful reassurance. Acetaminophen remains the recommended first-line pain and fever reliever during pregnancy, and this evidence suggests its cautious use does not carry the neurodevelopmental risk previously feared. However, as with any medication during pregnancy, use should remain purposeful and at the lowest effective dose.
Key Findings
- Sibling-matched analyses showed prenatal acetaminophen had no link to autism (HR 1.00) or ADHD (HR 1.01).
- Negative-control analysis revealed earlier positive findings likely reflect maternal health differences, not drug effects.
- Pre-pregnancy acetaminophen use showed similar risk elevations, confirming confounding rather than causation.
- Results were consistent regardless of dose, timing, or frequency of acetaminophen use during pregnancy.
- Findings align with four prior international sibling studies all showing no increased neurodevelopmental risk.
Methodology
This is a news report summarizing a peer-reviewed study published in JAMA Internal Medicine, a high-credibility journal. The study used a large population-based sibling-matched cohort design in Hong Kong, with negative-control analyses to address confounding — considered a methodologically rigorous approach for observational pregnancy research.
Study Limitations
The study is based on a Hong Kong population, which may limit generalizability to other ethnic or healthcare contexts. The article does not detail how acetaminophen exposure was measured or validated, which is important for observational pregnancy research. Primary source review of the full JAMA Internal Medicine paper is recommended for clinical decision-making.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: